Invasive anal or penile cancer · 10‐ to 26‐year‐old males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Penile or anal intraepithelial neoplasia at up to 3‐year · 10‐ to 26‐year‐old males
Three doses HPV vaccine showed no clear difference in penile or anal intraepithelial neoplasia at up to 3‐year compared with control (low certainty).
1 finding from 1 review
External genital lesions (any genotype) at up to 3‐year · 10‐ to 26‐year‐old males
Three doses HPV vaccine probably leads to lower external genital lesions (any genotype) at up to 3‐year compared with control (moderate certainty).
1 finding from 1 review
Anogenital warts at up to 3‐year · 10‐ to 26‐year‐old males
Three doses HPV vaccine probably leads to lower anogenital warts at up to 3‐year compared with control (moderate certainty).
1 finding from 1 review
Overall local/injection site adverse events at 15‐day · 10‐ to 26‐year‐old males
Three doses HPV vaccine leads to higher overall local/injection site adverse events at 15‐day compared with control (high certainty).
1 finding from 1 review
Overall systemic events and general symptoms · 10‐ to 26‐year‐old males
Three doses HPV vaccine showed no clear difference in overall systemic events and general symptoms at 15‐day compared with control (moderate certainty).
1 finding from 1 review
Serious adverse events at up to 3‐year · 10‐ to 26‐year‐old males
It is very uncertain whether three doses HPV vaccine changes serious adverse events at up to 3‐year compared with control (very low certainty).
1 finding from 1 review
Mortality at up to 3‐year · 10‐ to 26‐year‐old males
Three doses HPV vaccine may leads to lower mortality at up to 3‐year compared with control (low certainty).
1 finding from 1 review
Clinical and harms outcomes* · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Antibody response (immunogenicity) · 9‐ to 15‐year‐old females
Two doses of HPV vaccine probably leads to lower antibody response (immunogenicity) compared with three doses of HPV vaccine (moderate certainty).
1 finding from 1 review
High‐grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and cervical cancer · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
High‐grade cervical, vulval, and vaginal disease · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall local/injection site adverse events · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall systemic events and general symptoms · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events at up to 5‐year · 9‐ to 15‐year‐old females
It is very uncertain whether two doses of HPV vaccine changes serious adverse events at up to 5‐year compared with three doses of HPV vaccine (very low certainty).
1 finding from 1 review
Mortality at up to 5‐year · 9‐ to 15‐year‐old females
Two doses of HPV vaccine showed no clear difference in mortality at up to 5‐year compared with three doses of HPV vaccine (low certainty).
1 finding from 1 review